Haemonetics Corp (HAE) is now in the Undervalued zone, suggesting that its current forward PE ratio of 15.49 is considered Undervalued compared with the five-year average of 20.34. The fair price of Haemonetics Corp (HAE) is between 67.14 to 103.51 according to relative valuation method. Compared to the current price of 63.88 USD , Haemonetics Corp By Undervalued By 4.86%.

Relative Value

Fair Zone

67.14-103.51

Current Price：63.88

4.86%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Haemonetics Corp (HAE) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Haemonetics Corp (HAE) has a current Price-to-Book (P/B) ratio of 4.40. Compared to its 3-year average P/B ratio of 4.40, the current P/B ratio is approximately 0.07% higher. Relative to its 5-year average P/B ratio of 4.58, the current P/B ratio is about -3.89% higher. Haemonetics Corp (HAE) has a Forward Free Cash Flow (FCF) yield of approximately 6.84%. Compared to its 3-year average FCF yield of 3.76%, the current FCF yield is approximately 81.85% lower. Relative to its 5-year average FCF yield of 3.09%, the current FCF yield is about 121.60% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for HAE competitors is 3.28, providing a benchmark for relative valuation. Haemonetics Corp Corp (HAE.N) exhibits a P/S ratio of 2.76, which is -15.77% above the industry average. Given its robust revenue growth of -2.75%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of HAE increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of HAE in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is HAE currently overvalued or undervalued?

What is Haemonetics Corp (HAE) fair value?

HAE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Haemonetics Corp (HAE) is between 67.14 to 103.51 according to relative valuation method.

How does HAE's valuation metrics compare to the industry average?

The average P/S ratio for HAE's competitors is 3.28, providing a benchmark for relative valuation. Haemonetics Corp Corp (HAE) exhibits a P/S ratio of 2.76, which is -15.77% above the industry average. Given its robust revenue growth of -2.75%, this premium appears unsustainable.

What is the current P/B ratio for Haemonetics Corp (HAE) as of Mar 03 2026?

As of Mar 03 2026, Haemonetics Corp (HAE) has a P/B ratio of 4.40. This indicates that the market values HAE at 4.40 times its book value.

What is the current FCF Yield for Haemonetics Corp (HAE) as of Mar 03 2026?

As of Mar 03 2026, Haemonetics Corp (HAE) has a FCF Yield of 6.84%. This means that for every dollar of Haemonetics Corp's market capitalization, the company generates 6.84 cents in free cash flow.

What is the current Forward P/E ratio for Haemonetics Corp (HAE) as of Mar 03 2026?

As of Mar 03 2026, Haemonetics Corp (HAE) has a Forward P/E ratio of 15.49. This means the market is willing to pay $15.49 for every dollar of Haemonetics Corp's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Haemonetics Corp (HAE) as of Mar 03 2026?

As of Mar 03 2026, Haemonetics Corp (HAE) has a Forward P/S ratio of 2.76. This means the market is valuing HAE at $2.76 for every dollar of expected revenue over the next 12 months.

HAE Valuation